Clinical Trials on Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral

Total 22 results

Merz North America, Inc.
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines (ULTRA I)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

United States
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. (ULTRA II)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Germany
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

United States, Canada
Merz North America, Inc.

Terminated

Longitudinal Evaluation and Real-world Evidence of NT201

Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Merz Aesthetics GmbH
Merz Pharmaceuticals GmbH

Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States, Germany
Allergan

Completed

BOTOX® in the Treatment of Upper Facial Lines in Japan

Glabellar Lines | Frown Lines | Crow's Feet Lines | Upper Facial Rhytides

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Ipsen

Terminated

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (LONG-SET)

Moderate Upper Facial Lines | Severe Upper Facial Lines

Germany
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Ipsen

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (LANTIC)

Moderate to Severe Upper Facial Lines

Germany, France
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

Glabellar Frown Lines | Facial Rhytides

Canada
Mohamed Hayder Oleish Salih

Completed

Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique

Glabellar Frown Lines | Wrinkle | Facial Expression | Rhytides

Egypt
University of New Mexico
AbbVie

Not yet recruiting

Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

Glabellar Frown Lines | Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin | Zinc Supplementation for Botulinum Toxin Treatment of the Forehead | Botulinum Toxin, Cosmetic | Adjuvant Oral Zinc and Botulinum Toxin

3

Subscribe